Century Therapeutics, Inc. develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.The company's lead product candidate is CNTY-101, which targets CD19 for relapsed, refractory B-cell lymphoma. It is also developing a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma.
